Physician profile
Sharon J Dellinger
NPI 1932213584
$4,380.52
in general payments reported to CMS, 2019-2025
25 companies · $1,485 in 2025
The $1,485 reported for 2025 was more than what 90% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $264 · 2023: $995 · 2024: $1,636 · 2025: $1,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,997 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,996.66 |
| Education | $119.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,236.34 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $548.49 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $462.70 | 2022-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $419.76 | 2023-2025 | Tremfya, Stelara, Simponi |
| Phathom Pharmaceuticals, INC. | $237.95 | 2024-2025 | Voquezna |
| Celgene Corporation | $228.77 | 2022-2024 | Zeposia |
| Gilead Sciences, INC. | $180.60 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $158.72 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $153.50 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $105.44 | 2024 | |
| Madrigal Pharmaceuticals | $98.30 | 2025 | Rezdiffra |
| Celltrion USA INC. | $88.30 | 2024-2025 | Vegzelma, Zymfentra |
| Nestle Healthcare Nutrition INC. | $70.17 | 2023 | |
| Genzyme Corporation | $68.54 | 2024-2025 | |
| Intercept Pharmaceuticals, INC. | $66.99 | 2023-2024 | Ocaliva |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $58.04 | 2024 | Sucraid |
| Pfizer INC. | $33.02 | 2023-2024 | |
| Evoke Pharma, INC. | $29.81 | 2023-2024 | Gimoti |
| Lilly USA, LLC | $25.24 | 2024 | Omvoh |
| Vivus LLC | $23.53 | 2025 | Pancreaze |
| Novo Nordisk INC | $23.11 | 2025 | Wegovy |
| Exact Sciences Corporation | $22.94 | 2025 | Cologuard Collection Kit |
| Redhill Biopharma INC. | $15.48 | 2023 | Talicia |
| Braintree Laboratories, INC. | $14.30 | 2025 | Suflave, Sutab |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Dellinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.